Transforming the NCI Clinical Trials Program and Operational Efficiency:
|
|
- Arabella Singleton
- 8 years ago
- Views:
Transcription
1 Transforming the NCI Clinical Trials Program and Operational Efficiency: Implications for Industry Collaborations Meg Mooney, MD, MBA Chief, Clinical Investigations Branch, CTEP, DCTD, NCI 3rd Annual Forum on Industry Collaboration with Cooperative Groups CBI Conference March 27, 2012
2 NCI Cooperative Group Clinical Trials Program: Update on Program Transformation & Progress on Operational Efficiency Scope of the Presentation: Update on Current Program & Progress on Transforming the Cooperative Group Program to the new NCI National Clinical Trials Network (NCTN) Update on Operational Efficiency Working Group (OEWG) Recommendations Implementation & Initial Results Update on Implementation of Common Clinical Data Management System (CDMS)
3 Overview of NCI Cooperative Group Program: A Distinctive NIH Program The NCI Clinical Trials Cooperative Group Program is distinctive among clinical trials programs supported by NIH: Groups funded by a Cooperative Agreement to conduct national trials at academic & community centers Group membership encourages volunteerism with direct involvement of investigators and patient advocacy in program and includes partnerships with international trial sites/organizations Funded Standing infra-structure to perform multiple types of trials (treatment, control, prevention) relatively inexpensively Long history of accomplishments resulting in improved outcomes and care for cancer patients Trials oriented toward mgt of diseases not agent-specific, with inclusion of correlative science, QOL, & symptom mgt questions Ability to focus on rare cancers for children and adults
4 Selected Major Accomplishments of Program: Over 30 Practice-Changing Clinical Trials including therapeutic agents and other modalities, with 4 announced in first 6 months of 2011 ACOSOG-Z0011 Surgery: SLND not inferior to Axillary Dissection in SLN+ BC NCIC-CTG MA.20 RT: Regional Nodal RT reduces LR & improves DFS in Node+ BC COG-AALL0232 Pediatrics: High Dose MTX improves EFS in pediatric ALL RTOG Multimodality: Short-term ADT with RT improves OS in prostate cancer Over 10 FDA Indications - New Oncology Agents (Yr FDA Approval) Bevacizumab CRC (2006); NSCLC (2006); Renal Cell Cancer (2009) Imatinib mesylate Pediatric CML (2006); Adjuvant GIST (2008) Nelarabine T-ALL and T-LBL (2005) Rituximab Diffuse Large B-cell Lymphoma (2006); Follicular NHL (2006) Trastuzumab - Adjuvant Therapy for Early-stage Her2+ Breast Cancer (2006) Thalidomide Newly Diagnosed Multiple Myeloma (2006) Anti-GD2 Antibody (ch14.18) in Neuroblastoma (BLA Currently in Preparation) Examples: New Indications Generic Agents (Yr Publication/Press Release) Daunorubicin in AML (2009); Dexamethasone in Multiple Myeloma (2007)
5 Overview of the Current Program 3,100 Institutions 14,000 Investigators About 25,000 pts enrolled on tx trials annually Trials FY2006 FY2007 FY2008 FY2009 FY2010 FY2011 All Phases: Treatment Trials 27,263 24,289 25,540 29,063 23,299 19,462 Accrual Distribution FY : Phase 3: 82.0% Phase 2: 15.3% Phase 1/Pilot: 2.6%
6 Changing the NCI s Clinical Trials System to Meet the Needs of the 21 st Century 2005 Clinical Trials Working Group (CTWG) Set framework for some of the changes recommended by the Institute of Medicine (IOM) report such as involvement of the extramural community in evaluation of clinical trials by Scientific Steering Committees 2009 Operational Efficiency Working Group (OEWG) OEWG was an outgrowth of the CTWG and provided recommendations NCI has implemented system-wide to improve speed & efficiency of evaluation, design, development & conduct of clinical trials 2010 IOM Report on Clinical Cooperative Groups Structural and Organizational Recommendations related to consolidation & integration of Groups operations as well as other recommendations
7 Extensive Review & Stakeholder Input Revised NCI s Clinical Trials System Cooperative Group Chairs & Group Biostatisticians Cancer Center Directors NCI Website CTWG 2005 OEWG 2010 IOM 2010 ASCO Letter 2011 NCI Mailbox NCI Advisory Boards Company Partners Patient Advocates Academic & Community Sites/Investigators Professional Analysis STPI Oncology Professional Associations
8 Progress Toward Consensus Goals for a Transformed System Improve speed & efficiency of development & conduct of trials Implementation of operational efficiency timelines Implementation of 24/7 central registration & Common Data Mgt System for all trials & provision of NCI Central IRBs (Adult & Pediatric) Incorporate innovative science and trial design NExT multiple agents under development with external peer review & Clinical Assay Development Program (CADP) Implementation of BIQSFP program for integral & integrated biomarkers, imaging, and QOL studies in trials Encourage randomized phase 2 trials Improve trial prioritization, selection, support, & completion Disease-specific and specialty Steering Committees prioritize trials Implementation of slow accrual guidelines Ensure participation of patients & physicians in system Pilot initiatives for increased reimbursement for phase 2 and 3 trials and to assess physician & patient feedback on trials
9 Structure of the Program: January 2011
10 Next Steps in Transforming the System New RFA for Integrated National Clinical Trials Network (NCTN) NCI BSA voted unanimously to approve RFA Concept for NCTN in November Consolidated Organizational Structure with Funding for 1 Pediatric Group & up to 4 Adult Groups with Review Criteria Emphasizing Integration & Collaboration for Overall Scientific Achievement and Operational Efficiency Funding Model with Increased Per-Case Reimbursement for High-Performance Academic & Community Sites Competitive Integrated Translational Science Awards Revitalize Cancer Center & Academic Centers Role in the Network (U10 Academic Center awards)
11 Introducing A New Organizational Structure NCI National Clinical Trials Network (NCTN) Other NCI Dark Grant blue boxes Programs signify NCI Contract DEA reviewed, Programs grant-funded components under Extramural this RFA & Advisory Committees
12 Network Components Review Criteria Group Operations & Statistical Centers Reconfigure NCI/NIH external peer-review of System Emphasis on incentives for a national system with trials open to all qualified sites & sites able to credit any Group to which they belong Review of all Network Groups/components at same time Scientific evaluation will shift to evaluating Group role in national network, overall scientific strategy, innovation and quality (~50%) Review criteria for operational efficiency & collaborative management of Network (~50%) Coordination with other Network Groups, NCI programs, NCI investigators outside Groups (e.g., CCOPs, MB-CCOPs, Tumor Banks, Cancer Centers, SPORES, N01s/U01s, P01s, etc.)
13 Network Description & Review Criteria Lead Academic Participating Sites Description Multiple-PI grants for academic institutions with demonstrated scientific leadership in 1 adult Network Groups, substantial accrual, & excellent data quality ( high-performance sites) Targeted at NCI Comprehensive and Clinical Cancer Centers and other leading academic centers Review Criteria Meets accrual threshold set from trials across entire Network Expertise & leadership role in Group(s) Data quality Contributions to translational science within Group trials Scientific collaborations across Cancer Center/Institution & Network
14 Network Description & Review Criteria Integrated Translational Science Awards Description Multiple-PI grants to support prominent researchers for their expertise and efforts in incorporating molecular studies into Network trials & enabling acquisition of preliminary data for further research Laboratory-based researchers will also facilitate hand-off of early phase clinical trial findings into later phase, definitive trials Review Criteria Peer-review of quality of scientific approach & plans for integration of translational science into clinical trials Leverages independently funded laboratory resources with Group clinical specimens & data to benefit Group research aims Research area likely to benefit trial efforts across Network
15 Network Description & Review Criteria Core Services & Canadian Partner Network RT and Imaging Core Services Provides scientific leadership for incorporating appropriate QA & image data management for research trials involving RT & imaging Review Criteria for scientific leadership & expertise as Network-wide resource, integrated IT platforms for capturing and storing images, & efficient procedures for accessing site data for RT & image-related trial questions Canadian Collaborating Trials Network NCI Program has had long history of collaboration with Canadian sites and non-profit Canadian clinical trial organizations Review Criteria for ability to provide appropriate regulatory oversight for US Networks trials conducted in Canada, irrespective of which Group leads trial and to be full partners in accruing patients to US Network trials
16 Overview of RFA: Cooperative Agreement 6 FOAs and Estimated # Grants Network Component Mechanism (Duration) Est. Max. # Grants Frequency New Application Accepted? Multiple PI Option? Group Operations Centers U10 (5 Yrs) 5 Every 5 Years Yes Group Statistical & Data Mgt Centers U10 (5 Yrs) 5 Every 5 Years Yes Canadian Collaborating Network Integrated Translational Science Awards RT and Imaging Core Services U10 (5 Yrs) 1 Every 5 Years Yes U10 (5 Yrs) 1 to 5 Every 5 Years Yes U24 (5 Yrs) 1 to 2 Every 5 Years Yes Lead Academic Participating Sites U10 (5 Yrs) 30 to 40 Multiple dates within 5 Year period Yes
17 Tentative Timeline for Implementation BSA Concept Review Nov 2011 NCI DEA & NIH Review FOA/Guidelines Nov 2011 July 2012 New FOA Released/Published July 2012 Receipt Competing Applications Winter 2012 [Nov Feb 2013] Review Competing Applications Summer 2013 [May Aug 2013] NCAB Review Dec 2013 Rollout of Awards in FY2014 March 2014
18 NCI Cooperative Group Clinical Trials Program: Update on Program Transformation & Progress on Operational Efficiency Scope of the Presentation: Update on Current Program & Progress on Transforming the Cooperative Group Program to the new NCI National Clinical Trials Network (NCTN) Update on Operational Efficiency Working Group (OEWG) Recommendations Implementation & Initial Results Update on Implementation of Common Clinical Data Management System (CDMS)
19 Operational Efficiency Working Group (OEWG): Overview of Recommendations and Implementation Operational Efficiency Working Group (OEWG): New process to develop trials in an interactive & collaborative fashion initiated in March 2010 with timelines for target & absolute timelines for trial development (review of proposal to activation) Developed implementation plans to achieve targets As of Apr 2010: All Group treatment trials monitored per new timelines As of Jan 2011: All trials that do not achieve absolute deadlines do not go forward
20 Historical vs OEWG Target & Absolute Timelines Absolute = 730 Protocol terminated if absolute timelines not achieved
21 Implementation by NCI/CTEP & Groups of the OEWG Recommendations Hiring of New Staff Project Managers, Medical Editors New IT Tools Secure Website for monitoring reports with specific milestones New Processes Tracking study development timelines & enforcing deadlines Conference call process with investigators & Group Operations Offices to resolve outstanding issues Medical Editors create draft Consensus Reviews with set templates & use track changes for set changes to protocol document Modified/developed internal SOPs to streamline processes and improve communication Development of Time-Outs to Adjust Targets for FDA/Drug Supply/Contracting
22 OEWG Conference Call Process Conference calls between NCI & Group study team held to clarify issues/comments in Consensus Review to prevent review iterations that may otherwise slow the approval process. Conference calls occur at several key points: After early study proposal received (LOI / Concepts) After initial protocol submission Ad hoc 493 conference calls between April March 2012 for both Cooperative Group & NCI/CTEP early phase treatment trials: (94.6% of calls set up occurred) 176 calls for new LOI s 80 calls for new Concepts 155 calls for new Protocols 82 calls for studies submitted prior to 4/1/2010
23 # of Calendar Days NCI/CTEP Early Phase Studies (Cooperative Groups & Others) as of 3/1/ Absolute Deadline: 540 Days Days (Median) 362 Days (Median) OEWG Target Timeline: 210 Days 60 Days: LOI/Concept 60 Days: Initial Protocol 90 Days: Review / Activation 0 Historical Studies (n=149 studies activated 2006 to 2008) Post OEWG Studies (n= 52 studies submitted after Apr 1, 2010) For larger Phase 2 Concepts w/ 240 Day Target, Median = 381 Days (n=12)
24 # of Calendar Days NCI/CTEP Phase 3 Studies (Cooperative Groups) as of 3/1/2012 Absolute Deadline: 730 Days Days (Median) 320 Days (Median) Historical Studies (n=67 studies activated 2006 to2008) Post OEWG Studies (n= 6 studies submitted after Apr 1, 2010) OEWG Target Timeline: 300 Days 90 Days: LOI/Concept 90 Days: Initial Protocol 120 Days: Review / Activation
25 Comparison of Number of Protocol Revisions Prior to Activation (As of December 2011) Post OEWG Group Studies (All Phases) vs Historical Studies
26 Planned Changes in OEWG Processes & Timelines Elimination of Official Time-Outs to Adjust Targets Used in variable ways across the various Groups Target and absolute deadlines would be the official metrics tracked without respect to or adjustment for timeouts Implementation March 2012 New Absolute Deadlines Decrease for Early Phase Studies (including larger Phase 2 Concepts) from 540 to 450 days Decrease for Phase 3 Studies from 730 to 540 days Implementation in Spring 2012 Institution of 6 Month Deadline for CTEP CRADA Agreements
27 New Absolute Deadline: Application to Group Early Phase Studies ( ) Change Absolute deadline of Early Phase (LOI) Studies & Phase 2 Concepts from 540 days to 450 days 1 In- Review LOI has surpassed the new proposed deadline 1 In-Review Phase 2 Concept has surpassed the new proposed deadline Studies Submitted Under OEWG (April 1 st, 2010) & Activated
28 New Absolute Deadline: Application to Phase 3 Concepts ( ) Change Phase 3 Concept Absolute Deadline from 730 days to 540 days No In-Review studies have surpassed the 540 day proposed deadline. Studies Submitted Under OEWG (April 1 st, 2010) & Activated
29 NCI Cooperative Group Clinical Trials Program: Update on Program Transformation & Progress on Operational Efficiency Scope of the Presentation: Update on Current Program & Progress on Transforming the Cooperative Group Program to the new NCI National Clinical Trials Network (NCTN) Update on Operational Efficiency Working Group (OEWG) Recommendations Implementation & Initial Results Update on Implementation of Common Clinical Data Management System (CDMS)
30 What is a Clinical Data Management System (CDMS)? Tool(s) or processes that support: Data collection Remote Data Capture (RDC) Data coding Standard libraries - Common Toxicity Criteria (CTCAE) Data management Discrepancy, delinquency, communication, correction Preparation of data for analysis Affects the entire research organization Science, safety, regulatory, operations, financial mgt, administration, Group staff, site staff
31 Need for CDMS Related to Consensus Goals on Transformation of Clinical Trials System IOM 2010 Report More resources for rapid implementation of a common electronic registration & data capture system would increase consistency across trials, conserve resources by: Reducing workload associated w/ patient enrollment & f/u Allow for more timely review of the data from a trial Enhance the knowledge gained from a trial Standardized case report forms would ease the burden of regulatory oversight and lead to better compliance ~2009: CBIIT RFP (selection of Medidata Rave) 2010: Initiate NCI common CDMS for Groups
32 Requirements to Deploy A Common CDMS for the Group Program Standard approach to: Application (Medidata Rave): Complete Core Configuration: Complete Business practices: Ongoing Data delinquency rules Integration with Global applications: Ongoing Pt enrollment, NCI accrual and adverse event reporting, User-name/password/Role (single sign-on) Case Report Forms: Ongoing Cancer Data Standards Registry and Repository (cadsr)
33 Balancing Act: Network vs Local Challenges Network Local (Adopting Organization) Use Working Groups to identify and develop Standards and/or best business practices
34 Working Group Areas Priority One (Required for launch) Core configuration Validation Data quality Data elements (i.e. ecrfs) Study build Study conduct User Management Integration Metrics Priority Two (start fall 2011) RDC Training Auditing Priority Three (TBD) Reporting Stat issues - Analysis/Deviations Ancillary studies
35 Group Deployment Plan (start 4/1/11) Stage 1 0 to 90 days Start Apr 1, 2011 First 3 sites (Alpha) begin deployment (start of stage) Allow 1yr to implement Stage 2 91 to 180 days Start Jul 1, 2011 Second 3 sites (Bravo) begin deployment (start of stage) 9-months to implement Alpha sites continue deployment activities Stage to 270 days Start Oct 1, 2011 Third 3 sites (Charlie) begin deployment (start of stage) 9-months to implement Bravo sites continue deployment activities Alpha sites complete deployment (end of stage) Target completion Alpha/Bravo stage Spring 2012 Charlie stage Summer 2012
36 What Will this Mean for Collaboration with Industry? Common Data Management System and Harmonized/Shared Policies and Procedures within a Transformed System Should ease many administrative challenges of collaboration in the Program (one general approach) & aid transformation to a Network Should increase ability to address issues related to FDA and other regulatory entities, AE reporting, common CRFs in a unified manner Increased Operational Efficiency and Shared Goals for Accruing to National Trials Should provide greater confidence regarding commitment to trials by the entire US network & activation of trials, reducing risk of collaboration on a trial that is not widely supported Should help in key areas of delay in development Increased Ability to Conduct Trials in Rare Tumors and Patient Populations within a Transformed System Ex: Trials in adolescent population between COG & adult Groups
A Common Clinical Data Management System (CDMS) for the Cooperative Groups. Mike Montello November 9, 2011 v2a Montellom@mail.nih.
A Common Clinical Data Management System (CDMS) for the Cooperative Groups Mike Montello November 9, 2011 v2a Montellom@mail.nih.gov Presentation Purpose and Outline Purpose: Provide a status update regarding
More informationMEDIDATA/RAVE. from A Biostatistician s Perspective
MEDIDATA/RAVE from A Biostatistician s Perspective Presented by: Mehmet Kocak, Ph.D. Assistant Professor at, UTHSC Resources: www.ctsu.org www.mdsol.com Report of the Clinical Trials Working Group of the
More informationCTSU Operational ET-CTN. April 21, 2013
CTSU Operational Support Services for the ET-CTN Early Drug Development tmeeting April 21, 2013 1 Presentation Agenda Describe the Objectives of Consolidating ET- CTN Support Services Provide an Overview
More informationCTEP Workshop. An Overview of the NCI s Cancer Therapy and Evaluation Program (CTEP) CTEP s Mission. Workshop Objectives. NCI Organizational Structure
CTEP Workshop Elizabeth Ness, RN, MS Director, Staff Development Center for Cancer Research National Cancer Institute Workshop Objectives At the end of this workshop, participants will be able to: Discuss
More informationIntroduction to Data Auditing
How did we get here?? Introduction to Data Auditing David Hurd, M.D. Interim Chair, Data Audit Committee Wake Forest University School of Medicine CALGB Audit Preparation Workshop, June 2007 National Cancer
More informationFriday, May 2. Clinical Trials: Is Your Staff Competent? Session 10:15 11:45 am Ballroom C
Session 10:15 11:45 am Ballroom C Clinical Trials: Is Your Staff Competent? What fundamental skills and knowledge should clinical trials nurses have? In response to questions from its members about how
More informationProposed Evaluation Plan for Assessing Implementation of the Clinical Trials Working Group (CTWG) Initiatives
Proposed Evaluation Plan for Assessing Implementation of the Clinical Trials Working Group (CTWG) Initiatives Report of the CTWG Evaluation Working Group of the Clinical Trials and Translational Research
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More informationTHE EVOLVING BUSINESS MODEL FOR
THE EVOLVING BUSINESS MODEL FOR CLINICAL RESEARCH CHRIS BEARDMORE CHIEF EXECUTIVE OFFICER 6100 CENTER DRIVE, SUITE 600 LOS ANGELES, CA 90045 (424) 208-8866 CHRIS@TRMLLC.COM WWW.TRMLLC.COM Personalized
More informationGOG Foundation/Partners Program Overview 2015
GOG Foundation/Partners Program Overview 2015 Philip J. DiSaia, MD President GOG Foundation Larry J. Copeland, MD Vice President GOG Foundation GOG FOUNDATION/PARTNERS PROGRAM Basic Premise The Partners
More informationData Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.
Data Management & Case Report Form Development in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 3, 2015 Marge Good, RN, MPH, OCN Nurse Consultant Division of
More informationEffective Date: October 2015
University of Maryland Greenebaum Cancer Center UMGCC Standard Operating Procedure Title: Data & Safety Monitoring Plan Effective Date: October 2015 Procedure No: DSM001 University of Maryland Greenebaum
More informationYale Cancer Center Data and Safety Monitoring Committee Charter
Yale Cancer Center Data and Safety Monitoring Committee Charter Purpose/Mission The purpose of the Yale Cancer Center (YCC) Data and Safety Monitoring Committee (DSMC) is to provide ongoing data and safety
More informationDuke Maestro Care and Clinical Research: 1 st Town Hall Meeting
6// Duke Maestro Care and Clinical Research: st Town Hall Meeting Dean Nancy Andrews, MD, PhD Dr. Iain Sanderson, Chief Research and Academic Information Officer. Dr. Mark Stacy, Vice Dean for Clinical
More informationSTTR PROGRAMMATIC INVESTMENT GRANT APPLICATION
2016 STTR PROGRAMMATIC INVESTMENT GRANT APPLICATION Application Deadline: November 16, 2015 November 30, 2015 BLADDER BRAIN BREAST COLORECTAL HEAD & NECK LUNG OVARY PANCREAS PROSTATE SARCOMA APPLICATION
More informationUse of the Epic Electronic Health Record for Comprehensive Clinical Research Management at Duke
Use of the Epic Electronic Health Record for Comprehensive Clinical Research Management at Duke Iain Sanderson, BM, BCh, Denise Snyder, MS, RD, Terry Ainsworth, RN, MS, ACNP, Cory Ennis, MS, Julie McCauley,
More informationTransforming NCI s Clinical Trials System
Transforming NCI s Clinical Trials System James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute, NIH Implementing a National Cancer Clinical Trials System
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationScientific Plan and Structure Established for NRG Oncology
Scientific Plan and Structure Established for NRG Oncology Dateline Saturday, January 26, 2013 With the submission of the NRG Oncology grant proposal to the National Cancer Institute (NCI) on January 15,
More informationClinical Trials: The Crux of Cancer Innovation
Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationpcodr Performance Metrics Report
pcodr Performance Metrics Report April 2015 TABLE OF CONTENTS EXECUTIVE SUMMARY...ii Operations...ii Transparency...ii Stakeholder Engagement... iii Looking Ahead... iii 1. INTRODUCTION... 1 2. PERFORMANCE
More informationWhat s Next for Data Sharing: Insight from the NIH Experience
What s Next for Data Sharing: Insight from the NIH Experience Jerry Sheehan Assistant Director for Policy Development National Library of Medicine National Institutes of Health SHARE In-Person Meeting
More informationJeri & Noboru Oishi Symposium
Jeri & Noboru Oishi Symposium Using the NCI CIRB SWOG Fall Group Meeting Jeanne Hyatt M. Adler, Regency RN, in Chicago MPH, CCRP October 7-10, 2015 CTEP/DCTD/NCI9, 2013 AND LaTisa Hernandez, PA, CCRC,
More informationGregory Milman National Institute of Allergy and Infectious Diseases gmilman@niaid.nih.gov May 7, 2012
Secrets of NIH Small Business Grant Applications Gregory Milman National Institute of Allergy and Infectious Diseases gmilman@niaid.nih.gov May 7, 2012 Particularly Important Information Is Highlighted
More informationUnlocking the Full Value of Your Clinical Trials Management System (CTMS) Investment
Unlocking the Full Value of Your Clinical Trials Management System (CTMS) Investment May 28, 2014 YOUR MISSION OUR SOLUTIONS Huron Consulting Group Inc. All Rights Reserved. Huron is a management consulting
More informationKentucky Lung Cancer Research Program. 2010 Strategic Plan Update
Kentucky Lung Cancer Research Program 2010 Strategic Plan Update Approved by the KLCR Program Governance Board August 12, 2009 KLCR Program Strategic Plan Table of Contents Introduction... 3 GOAL 1: Investigator-Initiated
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationRegulatory Issues in Genetic Testing and Targeted Drug Development
Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationAdopting Site Quality Management to Optimize Risk-Based Monitoring
Adopting Site Quality Management to Optimize Risk-Based Monitoring Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective
More informationP/T 2B: 2 nd Half of Term (8 weeks) Start: 25-AUG-2014 End: 19-OCT-2014 Start: 20-OCT-2014 End: 14-DEC-2014
2014-2015 SPECIAL TERM ACADEMIC CALENDAR FOR SCRANTON EDUCATION ONLINE (SEOL), MBA ONLINE, HUMAN RESOURCES ONLINE, NURSE ANESTHESIA and ERP PROGRAMS SPECIAL FALL 2014 TERM Key: P/T = Part of Term P/T Description
More informationP/T 2B: 2 nd Half of Term (8 weeks) Start: 26-AUG-2013 End: 20-OCT-2013 Start: 21-OCT-2013 End: 15-DEC-2013
2013-2014 SPECIAL TERM ACADEMIC CALENDAR FOR SCRANTON EDUCATION ONLINE (SEOL), MBA ONLINE, HUMAN RESOURCES ONLINE, NURSE ANESTHESIA and ERP PROGRAMS SPECIAL FALL 2013 TERM Key: P/T = Part of Term P/T Description
More information2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February
More informationHow valuable is a cancer therapy? It depends on who you ask.
How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr
More informationPrepared by: Clinical Trials Monitoring Branch Cancer Therapy Evaluation Branch Division of Cancer Treatment and Diagnosis National Cancer Institute
NCI GUIDELINES FOR AUDITING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIALS NETWORK (NCTN) PROGRAM, COMMUNITY CLINICAL ONCOLOGY PROGRAM (CCOP) / NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (NCORP) AND
More informationThe Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum:
The National Working Group on Evidence-Based Health Care The Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum: Models of Patient/Consumer Inclusion August 2008 The Working
More informationGilead Clinical Operations Risk Management Program
Gilead Clinical Operations Risk Management Program Brian J Nugent, Associate Director 1 Agenda Risk Management Risk Management Background, Benefits, Framework Risk Management Training and Culture Change
More informationCancer Clinical Trials: In-Depth Information
Cancer Clinical Trials: In-Depth Information The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3)
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationClinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationLaurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
More informationHollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
More informationAPPLICATION ANNUAL WORK PLAN (ONE OBJECTIVE PER PAGE)
GOVERNANCE Objective 1A Ensure program success through effective governance structures. The successful applicant will be required to work with a representative advisory group developed in consultation
More informationHigh Country Nuclear Medicine Conference Clinical Decision Support, the Good, the Bad and the Ugly Sue Bunning, Director Health Policy and Regulatory
High Country Nuclear Medicine Conference Clinical Decision Support, the Good, the Bad and the Ugly Sue Bunning, Director Health Policy and Regulatory Affairs March 2, 2015 SNMMI s History Founded in 1954
More informationNavigating GIST. The Life Raft Group June 12, 2008
Navigating GIST Clinical Trials The Life Raft Group June 12, 2008 Some observations: Annually, only 3% of adult patients participate in cancer clinical trials. Lara et. al; Evaluation of factors affecting
More informationMesothelioma Applied Research Foundation www.curemeso.org
Mesothelioma Applied Research Foundation www.curemeso.org Board of Directors Michael Becich PhD Gen. Steven Blum Lee Krug MD David Ettinger MD Axel Ranier Richard Mosca Erica Iacono Terry Lynch Hanne Minz
More informationClinical Cancer Research: Alternative IRB Models and Enhancing Progress
Clinical Cancer Research: Alternative IRB Models and Enhancing Progress Lowell E. Schnipper, M.D. Berenson Professor of Medicine Chief, Hematology-Oncology Beth Israel Deaconess Medical Dynamics of Clinical
More informationClinical Trials Reporting Program (CTRP) and Clinicaltrials.gov (CT.gov) Helpful tips and guidance
Clinical Trials Reporting Program (CTRP) and Clinicaltrials.gov (CT.gov) Helpful tips and guidance Objectives NCI s Clinical Trials Reporting Program (CTRP) Overview CTRP What is it? CTRP is an NCI mandated
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology
ASCO Initiatives in Personalized Medicine Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology Financial Disclosures No financial relationships to disclose.
More informationFiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements
Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements PCRP AWARD MECHANISMS WITH EMPHASIS ON RESOURCES Clinical Consortium Award
More informationMeeting Priorities of Biotech & Small Pharma Companies
Meeting Priorities of Biotech & Small Pharma Companies Dr. Andreas Orfanos, MBBCH,FFPM,MBA Thrasos Therapeutics Inc. Vice President Clinical Research & Development 28 Oct 2015 Montreal Technoparc Private,
More informationNCI Community Cancer Centers Program Program Overview Ascension Health St. Vincent Indianapolis Hospital
A. Name and location of hospital:, Indianapolis, IN B. Name of cancer center: St. Vincent Oncology Center C. Identify PI and key personnel with contact information for each pilot focus areas: a. Disparities
More informationMedicare Advantage and Part D Proposed Rule for Contract Year 2015 Prepared for Healthcare Leadership Council. January 2014 Avalere Health LLC 1
Medicare Advantage and Part D Proposed Rule for Contract Year 2015 Prepared for Healthcare Leadership Council January 2014 Avalere Health LLC 1 Overview On January 6, the Centers for Medicare & Medicaid
More informationReissuance of RFA-CA-08-504 Adult Brain Tumor Consortium
Reissuance of RFA-CA-08-504 Adult Brain Tumor Consortium Bhupinder S Mann, MBBS GU, HN and Adult Brain Cancers Therapeutics Clinical Investigations Branch CTEP DCTD NCI William C Timmer, PhD ABTC Program
More informationOncology Central MEDIA PACK 2016 SPONSORSHIP ADVERTISING NETWORKING
Oncology Central MEDIA PACK 2016 SPONSORSHIP ADVERTISING NETWORKING Client opportunities CONTENTS About us...02 Readership...04 Driving qualified leads...05 Our Journals...08 Editorial Calendar...10 Rate
More informationBarnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA
Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA This presentation is the property of DynPort Vaccine Company LLC, a CSC company, and
More informationClinical Trials and SPA Fall, 2014
Clinical Trials and SPA Fall, 2014 Laura Williams Frances Spalding Sponsored Projects Administration What to Expect Review of key clinical trial concepts A common clinical trial process How SPA fits in
More informationBasic Results Database
Basic Results Database Deborah A. Zarin, M.D. ClinicalTrials.gov December 2008 1 ClinicalTrials.gov Overview and PL 110-85 Requirements Module 1 2 Levels of Transparency Prospective Clinical Trials Registry
More informationP/T 2B: 2 nd Half of Term (8 weeks) Start: 24-AUG-2015 End: 18-OCT-2015 Start: 19-OCT-2015 End: 13-DEC-2015
2015-2016 SPECIAL TERM ACADEMIC CALENDAR For Scranton Education Online (SEOL), Masters of Business Administration Online, Masters of Accountancy Online, Health Administration Online, Health Informatics
More informationTHE SECRETS OF OUR SUCCESS
THE SECRETS OF OUR SUCCESS QUALITY OF LIFE STUDIES OF THE NCIC Andrea Bezjak, MDCM, MSc,, FRCPC Chair, NCIC CTG QOL Committee Outline of the Presentation Can we consider NCIC CTG QOL activities a success?
More informationGuidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationReport of the Clinical Trials Working Group of the National Cancer Advisory Board. Restructuring the National Cancer Clinical Trials Enterprise
Report of the Clinical Trials Working Group of the National Cancer Advisory Board Restructuring the National Cancer Clinical Trials Enterprise June 2005 CLINICAL TRIALS WORKING GROUP Chairman James H.
More informationPerspectives on Patient Recruitment
Webcast Perspectives on Patient Recruitment Sponsors: Presenters Moderator: Christiane Truelove Editor in Chief, R&D Directions Chris.Truelove@ubm.com Speakers: Dr. Bradley Vince, D.O., President and Medical
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationThe fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
More informationProcess Validation Workshops. Overview Session
Process Validation Workshops Overview Session 2 Session Objectives: Prepare staff for participating in a Process Validation Workshop Clarify the Purpose of Process Validation Workshops Clarify Expected
More informationRe: Advance Notice/Call Letter for Medicare Advantage Plans for Calendar Year (CY) 2014
March 1, 2013 Marilyn Tavenner, RN, BSN, MHA Acting Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services 200 Independence Avenue, SW Washington, D.C. 20201 Submitted
More informationPolicy of the National Institute of Nursing Research for Data and Safety Monitoring of Extramural Clinical Trials
Policy of the National Institute of Nursing Research for Data and Safety Monitoring of Extramural Clinical Trials Purpose and Scope This policy sets forth the National Institute of Nursing Research (NINR)
More informationInnovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring
Innovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring Brett Barber, Sr. Director, Strategic Resourcing Nicole Baker, Sr. Director, Strategic
More information2/25/2014. HRPP Compliance Institutional Review Board Regulatory Affairs Conflict of Interest
Site Based Clinical Research at Duke Mark Stacy, MD Professor of Neurology Vice Dean for Clinical Research Duke University School of Medicine Clinical Research Success: 2013 ClinicalTrials.gov RDSP compliance
More informationPutting Patients at the Heart of what Value Means
November 19, 2015 Robert Carlson, MD Chief Executive Officer National Comprehensive Cancer Network 275 Commerce Drive, Suite 300 Fort Washington, PA 19034 Dear Dr. Carlson, The undersigned organizations
More informationFrom: Steve Berberich, Vice President of Technology and Corporate Services and Chief Financial Officer
California Independent System Operator Corporation Memorandum To: ISO Board of Governors From: Steve Berberich, Vice President of Technology and Corporate Services and Chief Financial Officer Date: September
More information2016 PANCREATIC CANCER ACTION NETWORK PRECISION PROMISE CLINICAL TRIAL CONSORTIUM SITES. Guidelines and Application Instructions
2016 PANCREATIC CANCER ACTION NETWORK PRECISION PROMISE CLINICAL TRIAL CONSORTIUM SITES Guidelines and Application Instructions CONTENTS I. GUIDELINES 1 BACKGROUND 1 PRECISION PROMISE EXECUTIVE COMMITTEE
More informationMovember Clinical Trial Award (CTA)
Movember Clinical Trial Awards Part 1: Overview Participating Organisation (s) Funding Category Description The Movember Foundation and Prostate Cancer Foundation of Australia Movember Clinical Trial Award
More informationBUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE
BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE Jean Toth-Allen, Ph.D. Biophysicist Office of Good Clinical Practice Office of the Commissioner May 14, 2012 1 Overview I. Background why we are
More informationPROGRAM OVERVIEW. Center for Clinical and Translational Research Cancer and Blood Disorders Research Pilot Funds I. PURPOSE
PROGRAM OVERVIEW I. PURPOSE The purpose of the Clinical Program is to cultivate outstanding new research, stimulate preliminary data in novel research directions, and ultimately to launch new nationally-funded
More informationNIH Grants Overview: Scientific Review Branch. Management
NIH Grants Overview: Scientific Review and Grants Management Lynn Mertens King, PhD Chief Scientific Review Branch Division of Extramural Activities NIDCR Amy McGuire Grants Management Specialist Grants
More informationCall 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
More informationPage 191 TITLE 21 FOOD AND DRUGS 355 1
Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken prior
More informationThe CTSA Program: Collaborative Innovation for Translational Research
The CTSA Program: Collaborative Innovation for Translational Research Petra Kaufmann, MD, MSc Director, Division of Clinical Innovation NCATS ADVISORY COUNCIL MEETING JUNE 18, 2015 Transforming the CTSA
More informationThe University of Michigan Health System Peking University Health Science Center Joint Institute for Translational and Clinical Research
The University of Michigan Health System Peking University Health Science Center Joint Institute for Translational and Clinical Research CALL FOR PROPOSALS Purpose The University of Michigan Health System
More informationSection 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership
Section 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership PROJECT MANAGEMENT - SCOPE DEFINITION AND MANAGEMENT Understands the
More informationApplications are accepted on a rolling basis.
The University of Michigan Health System Peking University Health Science Center Joint Institute for Translational and Clinical Research Clinical Trial Grant Processes Purpose The University of Michigan
More informationORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS
ORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS INCORPORATE GENOMIC DATA INTO CLINICAL R&D KEY BENEFITS Enable more targeted, biomarker-driven clinical trials Improves efficiencies, compressing
More informationWhat Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationSharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com
SAMPLE CRA CV Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com Education: Masters of Science, Healthcare Administration, Capital City University,
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationThe NCI CIRB Initiative: Change and Growth
The NCI CIRB Initiative: Change and Growth Jacquelyn L. Goldberg, JD Head, CIRB Initiative U.S. DEPARTMENT HEALTH AND HUMAN SERVICES NATIONAL INSTITUTE OF CTTI June 12, 2014 HEALTH The CIRB Initiative
More informationOnCore Interfaces. UCSF Medical Center Care Technology Governance Meeting CTG - September 5 th, 2013
UCSF Medical Center Care Technology Governance Meeting CTG - September 5 th, 2013 Interfaces UCSF -Office of Research - 1 Requesting Phase 1 Prioritization - Will return to CTG for Phase 2 prioritization.
More informationTHE FUTURE OF CLINICAL TRIALS: NEW MODEL TO ENHANCE EFFICIENCY. Jeff Allen, PhD Executive Director Friends of Cancer Research
THE FUTURE OF CLINICAL TRIALS: NEW MODEL TO ENHANCE EFFICIENCY Jeff Allen, PhD Executive Director Friends of Cancer Research Current Challenges Each potential new therapy is typically tested independently
More informationMoving forward, where are we with Clinical Trials?
Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where
More informationLisa A. Benson, BS CCRP, CRCP 9 Vexation Hill Drive Rocky Hill, Connecticut 06067 Email: labenso@connecticutchildrens.
Lisa A. Benson, BS CCRP, CRCP 9 Vexation Hill Drive Rocky Hill, Connecticut 06067 Email: labenso@connecticutchildrens.org 860-214-7375 Education: 2007-2013 California Coast University Santa Ana, CA Bachelors
More informationNew Investigator Collaborations and Interactions: Regulatory
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité New Investigator Collaborations and Interactions: Regulatory NCIC Clinical Trials Group New Investigator Clinical Trials
More informationA Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations
More information